OTLK

Recent Form 4

Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.

Price (1 year)

Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.

Market snapshot

Signal

Bearish signalScored 2026-09-13

Despite a strong catalyst signal (insider cluster buying aligned with FDA approval of LYTENAVA and promising revenue projections), OTLK's severely distressed financial profile — with a current ratio of 0.38, negative…

The first sentence of the analysis written for OTLK on 2026-09-13 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.

Financial ratios

Sparkline shows each ratio oldest → newest (left → right).

How the latest year compares

For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower

Key metrics

Change by theme

Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.

Change over 1 year

Change over 5 years

Employee count

Peer market caps

Congressional trades

STOCK Act disclosures (90-day window)

Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.

No STOCK Act disclosures for this company in this window.

Recent news

• 2026-08-17 OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp Outlook Therapeutics targets a year-end 2026 U.S. LYTENAVA launch, with $50M-$75M in first-year net revenues and a ramp tied to reimbursement.
• 2026-08-16 Oncobiologics Q3 Earnings Call Highlights Oncobiologics (NASDAQ: OTLK) said it is preparing for the U.S. commercial launch of LYTENAVA after the Food and Drug Administration approved the product as the only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration, or wet AMD, in the United States. President and Chief Executive Officer Bob Jahr called the approval
• 2026-08-15 Contrasting Oncobiologics (NASDAQ:OTLK) & enGene (NASDAQ:ENGN) enGene (NASDAQ: ENGN - Get Free Report) and Oncobiologics (NASDAQ: OTLK - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations. Insider and Institutional Ownership 64.2% of enGene shares are
• 2026-08-14 Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript
• 2026-08-14 Oncobiologics Q3 Earnings Call Highlights Oncobiologics NASDAQ: OTLK said it is preparing for the U.S. commercial launch of LYTENAVA after the Food and Drug Administration approved the product as the only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration, or wet AMD, in the United States.
• 2026-08-14 Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates Outlook Therapeutics, Inc. (OTLK) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.44 per share a year ago.
• 2026-08-14 Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™ The only FDA-approved ophthalmic bevacizumab, LYTENAVA TM , addresses a significant need in the U.S. wet AMD market where bevacizumab is already widely used
• 2026-08-14 Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street''s Most Accurate Analysts Outlook Therapeutics, Inc. (NASDAQ:OTLK) will release its third quarter earnings report before the opening bell on Friday, Aug. 14.
• 2026-08-12 Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced the pricing of an underwritten public offering of 55,555,556 shares of its common stock and accompanying warrants to purchase up to an aggregate of 55,555,556 shares of its common stock. The combined public offering price of each share of common stock and accompanying warrant to purchase one share is $0.99. The accompanying warrants have an exercise price of $1.10 per share, will become exercisable immediately and will expire five years from the date of issuance. Outlook Therapeutics also granted the underwriters an option for a period of 30 days to purchase up to 8,333,333 additional shares of its common stock and/or warrants to purchase up to 8,333,333 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the securities in the offering are to be sold by Outlook Therapeutics. The offering is expected to close on August 14, 2026 subject to market and other conditions.
• 2026-08-12 Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants to purchase shares of its common stock. Outlook Therapeutics also intends to grant the underwriters a 30-day option to purchase additional shares of its common stock and/or accompanying warrants in an amount up to fifteen percent (15%) of the shares of its common stock and/or accompanying warrants offered in the public offering under the same terms and conditions. All of the securities in the proposed offering are to be sold by Outlook Therapeutics. The proposed offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.